Source: International Congress 2018 – Clinical challenges in respiratory infection
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
K. Yap (Singapore, Singapore), G. Tan (Singapore, Singapore), J. Abisheganaden (Singapore, Singapore). Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNAse) for pleural infection in an Asian population: Similar outcomes between 5mg and 10mg regimen. 4687

Member's Comments

No comment yet.

Related content which might interest you: Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019 The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 Effectiveness and safety of tissue plasminogen activators (t-PA) in complicated pleural effusion (CPE), what the correlation with time it stays in the pleural space? Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Intrapleural use of dornase alfa and tissue plasminogen activator are successful as treatment in pediatric empyema: a pilot study Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes Year: 2018 Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019 Year: 2019 Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) Source: Eur Respir J 2005; 26: Suppl. 49, 93s Year: 2005 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Safety, immunogenicity and pharmacokinetics (PK) of a 120 mg/kg/week dose of alpha1-proteinase inhibitor in alpha1-antitrypsin deficiency Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Soluble urokinase plasminogen activator receptor (suPAR) for the prediction of ventilator-associated pneumonia (VAP) Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection Source: ERJ Open Res, 8 (1) 00590-2021; 10.1183/23120541.00590-2021 Year: 2022 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020 Year: 2020 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Chronic inhalation toxicity study of nebulized alpha1 proteinase inhibitor (alpha1-PI), TAL6005, in rodents Source: Annual Congress 2010 - Models of airways disease Year: 2010 Intrapleural heparin or heparin combined with human recombinant DNAase is not effective in the treatment of empyema in a rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 348s Year: 2006